NasdaqCM - Delayed Quote USD

Immuron Limited (IMRN)

2.6400 +0.1500 (+6.02%)
At close: 4:00 PM EDT
2.6300 -0.01 (-0.38%)
After hours: 4:01 PM EDT
Currency in AUD All numbers in thousands
Download
Breakdown
TTM
6/30/2023
6/30/2022
6/30/2021
6/30/2020
Total Revenue
3,576.6390
1,804.7050
765.1930
145.7760
2,518.5660
Cost of Revenue
1,115.0640
495.5580
241.6910
51.0710
688.8360
Gross Profit
2,461.5750
1,309.1470
523.5020
94.7050
1,829.7300
Operating Expense
5,332.2820
4,715.6670
3,640.9150
8,048.2130
4,874.5610
Operating Income
-2,870.7070
-3,406.5200
-3,117.4130
-7,953.5080
-3,044.8310
Net Non Operating Interest Income Expense
206.6010
106.6710
15.6010
-4.5570
-21.6310
Other Income Expense
-1,217.2000
-486.6580
247.5580
-426.4000
139.2560
Pretax Income
-3,881.3060
-3,786.5070
-2,854.2540
-8,384.4650
-2,927.2060
Net Income Common Stockholders
-3,881.3060
-3,786.5070
-2,854.2540
-8,384.4650
-2,927.2060
Diluted NI Available to Com Stockholders
-3,881.3060
-3,786.5070
-2,854.2540
-8,384.4650
-2,927.2060
Basic EPS
-0.68
-0.66
-0.50
-1.52
-0.66
Diluted EPS
-0.68
-0.66
-0.50
-1.52
-0.66
Basic Average Shares
5,694.9590
5,694.9590
5,689.4920
5,526.5560
4,409.8340
Diluted Average Shares
5,694.9590
5,694.9590
5,689.4920
5,526.5560
4,409.8340
Total Operating Income as Reported
-3,652.6480
-3,568.8380
-2,869.8550
-8,379.9080
-2,905.5750
Rent Expense Supplemental
--
--
--
--
51.9730
Total Expenses
6,447.3460
5,211.2250
3,882.6060
8,099.2840
5,563.3970
Net Income from Continuing & Discontinued Operation
-3,881.3060
-3,786.5070
-2,854.2540
-8,384.4650
-2,927.2060
Normalized Income
-3,099.3440
-3,624.1890
-3,101.8120
-7,958.0650
-3,066.4620
Interest Income
215.7590
116.3230
21.7850
9.2040
--
Interest Expense
9.1580
9.6520
6.1840
13.7610
21.6310
Net Interest Income
206.6010
106.6710
15.6010
-4.5570
-21.6310
EBIT
-3,872.1480
-3,776.8550
-2,848.0700
-8,370.7040
-2,905.5750
EBITDA
-3,872.1480
-3,728.1930
-2,805.4640
-8,327.0420
-2,861.5190
Reconciled Cost of Revenue
1,115.0640
495.5580
241.6910
51.0710
688.8360
Reconciled Depreciation
42.6060
48.6620
42.6060
43.6620
44.0560
Net Income from Continuing Operation Net Minority Interest
-3,881.3060
-3,786.5070
-2,854.2540
-8,384.4650
-2,927.2060
Total Unusual Items Excluding Goodwill
-781.9620
-162.3180
247.5580
-426.4000
139.2560
Total Unusual Items
-781.9620
-162.3180
247.5580
-426.4000
139.2560
Normalized EBITDA
-3,090.1860
-3,565.8750
-3,053.0220
-7,900.6420
-3,000.7750
6/30/2020 - 6/9/2017

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

APM Aptorum Group Limited
5.28
-3.65%
 
NRBO NeuroBo Pharmaceuticals, Inc.
3.1400
+2.61%
 
ATHE Alterity Therapeutics Limited
2.5100
+9.61%
 
CERO CERo Therapeutics Holdings, Inc.
1.3700
-2.84%
 
KTTA Pasithea Therapeutics Corp.
7.24
0.00%
 
BNTC Benitec Biopharma Inc.
6.90
0.00%
 
PBM Psyence Biomedical Ltd.
0.8589
+3.48%
 
GLMD Galmed Pharmaceuticals Ltd.
0.3916
+0.90%
 
EQ Equillium, Inc.
1.7100
-5.52%
 
LEXXW Lexaria Bioscience Corp.
0.7996
+12.62%